Key clinical point: The increased risk among hidradenitis suppurativa patients for any cancer and for several specific cancers including Hodgkin lymphoma, oral cavity and pharyngeal cancer, and nonmelanoma skin cancer support the need for increased cancer surveillance in this population.

Major finding: The overall cancer risk in hidradenitis suppurativa patients was significantly higher than that of controls, with an adjusted hazard ratio of 1.28.

Study details: The data come from a population-based cohort study including 22,468 hidradenitis suppurativa patients and 179,734 matched controls.

Disclosures: The study was supported by the National Research Foundation of Korea and the Korea Health Technology R&D Project. The researchers had no financial conflicts to disclose.